TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. has announced amendments to its Articles of Association following the placement of 19,000,000 new H Shares, which resulted in an increase in the company’s registered capital. The amendments, approved by the Board on August 22, 2025, reflect changes in the shareholding structure and authorize the management to carry out necessary procedures in compliance with domestic and international requirements. This strategic move is expected to enhance RemeGen’s operational capabilities and strengthen its market position.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company is focused on the development and commercialization of biologic drugs, with a market focus on innovative therapies in the fields of oncology, autoimmune, and ophthalmic diseases.
Average Trading Volume: 11,836,738
Technical Sentiment Signal: Buy
Current Market Cap: HK$47.71B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.